EP3469069A4 - Compositions and methods including b lymphocyte cell line expressing membrane immunoglobulin different from secreted immunoglobulin and cytolytic function - Google Patents

Compositions and methods including b lymphocyte cell line expressing membrane immunoglobulin different from secreted immunoglobulin and cytolytic function Download PDF

Info

Publication number
EP3469069A4
EP3469069A4 EP17811004.5A EP17811004A EP3469069A4 EP 3469069 A4 EP3469069 A4 EP 3469069A4 EP 17811004 A EP17811004 A EP 17811004A EP 3469069 A4 EP3469069 A4 EP 3469069A4
Authority
EP
European Patent Office
Prior art keywords
immunoglobulin
compositions
cell line
methods including
line expressing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP17811004.5A
Other languages
German (de)
French (fr)
Other versions
EP3469069A1 (en
Inventor
Roderick A. Hyde
Wayne R. Kindsvogel
Gary L. Mcknight
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Invention Science Fund II LLC
Original Assignee
Kota Biotherapeutics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/178,715 external-priority patent/US10233424B2/en
Application filed by Kota Biotherapeutics LLC filed Critical Kota Biotherapeutics LLC
Publication of EP3469069A1 publication Critical patent/EP3469069A1/en
Publication of EP3469069A4 publication Critical patent/EP3469069A4/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4612—B-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464493—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; Prostatic acid phosphatase [PAP]; Prostate-specific G-protein-coupled receptor [PSGR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464838—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0635—B lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/58—Prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EP17811004.5A 2016-06-10 2017-06-08 Compositions and methods including b lymphocyte cell line expressing membrane immunoglobulin different from secreted immunoglobulin and cytolytic function Pending EP3469069A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15/178,715 US10233424B2 (en) 2011-12-22 2016-06-10 Compositions and methods including cytotoxic B lymphocyte cell line expressing exogenous membrane immunoglobulin different from secreted immunoglobulin
PCT/US2017/036521 WO2017214376A1 (en) 2016-06-10 2017-06-08 Compositions and methods including b lymphocyte cell line expressing membrane immunoglobulin different from secreted immunoglobulin and cytolytic function

Publications (2)

Publication Number Publication Date
EP3469069A1 EP3469069A1 (en) 2019-04-17
EP3469069A4 true EP3469069A4 (en) 2020-01-22

Family

ID=60578909

Family Applications (1)

Application Number Title Priority Date Filing Date
EP17811004.5A Pending EP3469069A4 (en) 2016-06-10 2017-06-08 Compositions and methods including b lymphocyte cell line expressing membrane immunoglobulin different from secreted immunoglobulin and cytolytic function

Country Status (3)

Country Link
EP (1) EP3469069A4 (en)
CN (1) CN109563482A (en)
WO (1) WO2017214376A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10745468B2 (en) 2011-12-22 2020-08-18 Kota Biotherapeutics, Llc Compositions and methods for modified B cells expressing reassigned biological agents
EP3768707A4 (en) * 2018-03-19 2022-01-26 The Invention Science Fund II, LLC Compositions and methods for modified b cells expressing reassigned biological agents
EP3844290A4 (en) * 2018-09-13 2022-07-06 Ramot at Tel-Aviv University Ltd. Genetic engneering of b cell receptors and uses thereof in antigen-induced antibody secretion

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070071717A1 (en) * 2005-09-07 2007-03-29 University Of Iowa Research Foundation Treatment of B cells with IL-21 and B cell activators induces Granzyme B production
US20150283177A1 (en) * 2011-12-22 2015-10-08 Elwha Llc Compositions and Methods Including Recombinant B Lymphocyte Cell Line Including at Least One Endogenous Gene Expressing at Least One Endogenous Membrane Immunoglobulin Reactive to a First Antigen and Including at Least One Exogenously Incorporated Nucleic Acid Expressing at Least One Exogenous Secreted Immunoglobulin Reactive to a Second Antigen
US20160355783A1 (en) * 2011-12-22 2016-12-08 Elwha Llc Compositions and methods including b lymphocyte cell line expressing membrane immunoglobulin different from secreted immunoglobulin and cytolytic function

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US276A (en) 1837-07-17 Horse-power
US7378A (en) 1850-05-21 John g
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US6241982B1 (en) 1988-03-21 2001-06-05 Chiron Corporation Method for treating brain cancer with a conditionally lethal gene
DE4228162C1 (en) 1992-08-25 1994-01-13 Rajewsky Klaus Dr Method for replacing homologous gene segments from mammals in the germline of non-human mammals
US7147851B1 (en) * 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
JP4128227B2 (en) 1997-03-14 2008-07-30 バイオジェン・アイデック・インコーポレイテッド A method for incorporating a gene by homologous recombination at a specific site in a mammalian cell and a vector for carrying it out
US7807377B2 (en) 1998-10-20 2010-10-05 Salvatore Albani Method of isolating antigen-specific T cells employing artificial antigen presenting cells
DK1309347T3 (en) * 2000-08-11 2013-03-25 Mmrglobal Inc Method and composition for altering a B-cell mediated pathology
US6576464B2 (en) 2000-11-27 2003-06-10 Geron Corporation Methods for providing differentiated stem cells
US7939059B2 (en) 2001-12-10 2011-05-10 California Institute Of Technology Method for the generation of antigen-specific lymphocytes
NZ534205A (en) 2001-12-22 2006-04-28 Antibody A 4 Method for the generation of genetically modified vertebrate precursor lymphocytes and use thereof for the production of heterologous binding proteins
US7993864B2 (en) 2002-12-03 2011-08-09 Ucb Pharma S.A. Assay for identifying antibody producing cells
US7595379B2 (en) 2003-05-30 2009-09-29 Agensys, Inc. Antibodies and related molecules that bind to PSCA proteins
US7993919B2 (en) 2003-11-19 2011-08-09 The United States Of America As Represented By The Department Of Health And Human Services Method of inducing memory B cell development and terminal differentiation
EP2316920A1 (en) * 2009-10-30 2011-05-04 BioNTech AG Clonal expansion of B cells
US9175072B2 (en) 2011-12-22 2015-11-03 Elwha Llc Compositions and methods including recombinant B lymphocyte cell line including an exogenously incorporated nucleic acid expressing an exogenous membrane immunoglobulin reactive to a first antigen and including an endogenous gene expressing an endogenous secreted immunoglobulin reactive to a second antigen

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070071717A1 (en) * 2005-09-07 2007-03-29 University Of Iowa Research Foundation Treatment of B cells with IL-21 and B cell activators induces Granzyme B production
US20150283177A1 (en) * 2011-12-22 2015-10-08 Elwha Llc Compositions and Methods Including Recombinant B Lymphocyte Cell Line Including at Least One Endogenous Gene Expressing at Least One Endogenous Membrane Immunoglobulin Reactive to a First Antigen and Including at Least One Exogenously Incorporated Nucleic Acid Expressing at Least One Exogenous Secreted Immunoglobulin Reactive to a Second Antigen
US20160355783A1 (en) * 2011-12-22 2016-12-08 Elwha Llc Compositions and methods including b lymphocyte cell line expressing membrane immunoglobulin different from secreted immunoglobulin and cytolytic function

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MAGDALENA HAGN ET AL: "Why do human B cells secrete granzyme B? Insights into a novel B-cell differentiation pathway", ONCOIMMUNOLOGY, vol. 1, no. 8, 1 November 2012 (2012-11-01), pages 1368 - 1375, XP055449030, DOI: 10.4161/onci.22354 *
See also references of WO2017214376A1 *

Also Published As

Publication number Publication date
EP3469069A1 (en) 2019-04-17
CN109563482A (en) 2019-04-02
WO2017214376A1 (en) 2017-12-14

Similar Documents

Publication Publication Date Title
EP3534705A4 (en) Compositions and methods for cell cryopreservation
EP3456095A4 (en) System and method for cell switching
EP3265942A4 (en) Ensemble-based research recommendation systems and methods
EP3294307A4 (en) Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
EP3452089A4 (en) Bispecific binding proteins and uses thereof
EP3503920A4 (en) Anti-ctla4 antibodies
EP3283113A4 (en) Optimized pne-based chimeric receptor t cell switches and uses thereof
EP3268050A4 (en) Pore-forming protein conjugate compositions and methods
EP3664845A4 (en) Compositions and methods for disabling meyloid cells expressing trem1
EP3352760A4 (en) Cd3 binding polypeptides
EP3316909A4 (en) Anti-ntb-a antibodies and related compositions and methods
EP3324996A4 (en) Gdf11 binding proteins and uses thereof
EP3635100A4 (en) Compositions and methods for expressing otoferlin
EP3164159A4 (en) Bispecific cd33 and cd3 binding proteins
EP3383904A4 (en) Ctla-4 antibodies and uses thereof
EP3411068A4 (en) Bispecific binding proteins for pd-l1 and kdr
EP3070936A4 (en) Multi-purpose conference terminal and multi-purpose conference system
EP3280464A4 (en) Immune cell trapping devices and methods for making and using the same
EP3448981A4 (en) Compositions and methods for performing magnetibuoyant separations
EP3282755A4 (en) Relay node switching method and system
EP3447779A4 (en) Separator for electrochemical element and electrochemical element
EP3442543A4 (en) Compositions and methods for neuralgenesis
EP3293749A4 (en) Contactor and contactor system
EP3659336A4 (en) Digital lensing
EP3706558A4 (en) Compositions and methods for aquaculturing

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20190110

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: KOTA BIOTHERAPEUTICS, LLC

A4 Supplementary search report drawn up and despatched

Effective date: 20191220

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 35/17 20150101ALI20191216BHEP

Ipc: C12N 15/85 20060101ALI20191216BHEP

Ipc: C12N 5/0781 20100101AFI20191216BHEP

Ipc: A61K 35/12 20150101ALI20191216BHEP

Ipc: C07K 16/00 20060101ALI20191216BHEP

Ipc: A61K 38/17 20060101ALI20191216BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20210608

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: THE INVENTION SCIENCE FUND II, LLC

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20240119